LY4005130 for adults with severe alopecia areata (hair loss)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial compares intravenous LY4005130 with placebo in adults who have severe alopecia areata. Participants receive the study drug or placebo and are followed for roughly 48 weeks including screening, with periodic clinic visits and blood tests to measure how the body processes the drug and how the drug affects the body. Eligible participants have 50–90% scalp hair loss by SALT score with a current episode lasting 6 months to 4 years and must avoid other alopecia areata treatments during the study. The trial is sponsored by Eli Lilly and conducted at three clinical research centers in California.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have severe Alopecia Areata (AA) that meets all of the following criteria:

  * Hair loss encompassing ≥50% and ≤90% of the scalp, as measured by Severity of Alopecia Tool (SALT) score
  * The duration of the current episode of severe AA is at least 6 months and does not exceed 4 years
  * No significant spontaneous hair regrowth in the investigator's opinion for at least 6 months
  * Agree not to use any AA treatments during the study

Exclusion Criteria:

* Primarily "diffuse" type of AA (characterized by diffuse hair shedding)
* Are currently experiencing other forms of alopecia
* Participants who, in the opinion of the investigator, are currently experiencing or have a history of unstable concomitant disease that requires frequent hospitalizations, and/or frequent use of systemic immunosuppressants that may interfere with participation in the study
* Have had any major surgery within 8 weeks prior to screening or will require major surgery during the study
* Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness

Where it's running

• Center For Dermatology Clinical Research, Inc.
  Fremont, California, United States Recruiting
• Northridge Clinical Trials
  Northridge, California, United States Recruiting
• Cura Clinical Research - Santa Clarita - Kelly Johnson Parkway
  Santa Clarita, California, United States Recruiting
• Health Clinical Research, LLC
  Cutler Bay, Florida, United States Recruiting
• Brigham and Women's Hospital
  Boston, Massachusetts, United States Recruiting
• Revival Research Institute, LLC
  Troy, Michigan, United States Recruiting

Study contacts

• Study coordinator: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
• Email: LillyTrials@Lilly.com
• Phone: 1-317-615-4559

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Which works better for patchy hair loss: steroid injections or microneedling with steroid cream?

  This trial tests whether injecting triamcinolone into the skin or using microneedling with topical triamcinolone helps people with alopecia areata regrow hair more effectively.

  Recruiting Phase 4 Dow University of Health Sciences · Karachi, Sindh · NCT07926711

• Red Ultraviolet Hair Imaging and Hair Growth in Alopecia Areata

  This observational study checks if red fluorescence seen with UV hair imaging relates to disease features and how well hair regrows after standard intralesional corticosteroid treatment in adults with limited plaque-type alopecia areata.

  Recruiting Istanbul Training and Research Hospital · Istanbul · NCT07803874

• VC005 tablets in teens with severe alopecia areata

  This Phase 1 study tests VC005 tablets in adolescents with severe alopecia areata to see how the drug behaves in the body, whether it is safe, and if there are signs of benefit.

  Recruiting Phase 1 Jiangsu vcare pharmaceutical technology co., LTD · Beijing, Beijing Municipality · NCT07762443

• VC005 tablets in severe alopecia areata

  This study tests whether VC005 tablets work better than a placebo for adults with severe alopecia areata.

  Recruiting Phase 2 Jiangsu vcare pharmaceutical technology co., LTD · Beijing, Beijing Municipality · NCT07749716

• Ritlecitinib for patchy hair loss in teens and adults with alopecia areata

  This study tests whether ritlecitinib can help people 12 and older with patchy alopecia areata who have had symptoms for 6 months to 10 years.

  Recruiting at 30 sites Phase 3 Pfizer · Encinitas, California and 37 other locations · NCT07733765

• Alopecia Areata: looking at ferroptosis markers in blood

  This study tests whether levels of GPX4 and MDA in blood differ between people with alopecia areata and healthy controls.

  Recruiting Istanbul Training and Research Hospital · Istanbul, Cerrahpasa Mahallesi · NCT07733063

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.